Evaluation of oral factor Xa inhibitor‐associated extracranial bleeding reversal with andexanet alfa

INTRODUCTION: A reversal agent for factor Xa (FXa) inhibitors, andexanet alfa, was Food and Drug Administration approved without extensive study of clinical effectiveness, due to an overwhelming demand for FXa inhibitor reversal. In this study, we aimed to describe patient selection, clinical effect...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:J Thromb Haemost
Main Authors: Nederpelt, Charlie J., Naar, Leon, Sylvester, Katelyn W., Barra, Megan E., Roberts, Russel J., Velmahos, George C., Kaafarani, Haytham M. A., Rosenthal, Martin G., King, David R.
Format: Artigo
Sprog:Inglês
Udgivet: John Wiley and Sons Inc. 2020
Fag:
HAEMOSTASIS
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7589264/
https://ncbi.nlm.nih.gov/pubmed/32738161
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jth.15031
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker